Related Experiment Video
Updated: Jul 30, 2026
10:49
Intraspinal Cell Transplantation for Targeting Cervical Ventral Horn in Amyotrophic Lateral Sclerosis and Traumatic Spinal Cord Injury
Published on: September 18, 2011
BMS-188667 (Bristol-Myers Squibb)
1Department of Immunology, Merck Research Laboratories, Rahway, NJ 07065, USA. francis_dumont@merck.com
Idrugs : the Investigational Drugs Journal
|August 23, 2005
Summary
Bristol-Myers Squibb is developing CTLA4-Ig, an immunosuppressant immunoglobulin, for immunological disorders. This therapy is currently in Phase II trials for psoriasis and other autoimmune conditions.
Area of Science:
- Immunology
- Pharmacology
Background:
- Immunological disorders represent a significant unmet medical need.
- Immunosuppressant therapies are crucial for managing autoimmune diseases and preventing transplant rejection.
Purpose of the Study:
- To evaluate the therapeutic potential of CTLA4-Ig (abatacept) in various immunological disorders.
- To assess the efficacy and safety of CTLA4-Ig in conditions such as psoriasis, graft versus host disease, lupus erythematosus, rheumatoid arthritis, and allergic conditions.
Main Methods:
- CTLA4-Ig, an immunosuppressant immunoglobulin, is under development by Bristol-Myers Squibb.
- A Phase II clinical trial has been initiated for psoriasis.
- Collaborations are in place to explore indications including organ transplant rejection and autoimmune disorders.
Main Results:
- The abstract does not contain specific results from clinical trials.
- Development is ongoing across a range of inflammatory and autoimmune conditions.
Conclusions:
- CTLA4-Ig shows promise as a treatment for a spectrum of immunological and autoimmune diseases.
- Further clinical investigation, including Phase II trials for psoriasis, is underway to establish its therapeutic value.
